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________________________________________________________________________________ 
Abstract 
3-Nitrobenzanthrone (3-NBA) is a carcinogen occurring in diesel exhaust and air pollution. 
Using the 32P-postlabeling method, we found that 3-NBA and its human metabolite, 3-
aminobenzanthrone (3-ABA), are activated to species forming DNA adducts by cytosols and/or 
microsomes isolated from rat lung, the target organ for 3-NBA carcinogenicity, and kidney. Each 
compound generated identical five DNA adducts. We have demonstrated the importance of 
pulmonary and renal NAD(P)H:quinone oxidoreductase (NQO1) to reduce 3-NBA to species that 
are further activated by N,O-acetyltransferases and sulfotransferases. Cytochrome P450 (CYP) 1A1 
is the essential enzyme for oxidative activation of 3-ABA in microsomes of both organs, while 
cyclooxygenase plays a minor role. 3-NBA was also investigated for its ability to induce NQO1 and 
CYP1A1 in lungs and kidneys, and for the influence of such induction on DNA adduct formation 
by 3-NBA and 3-ABA. When cytosols from rats treated i.p. with 40 mg/kg bw of 3-NBA were 
incubated with 3-NBA, DNA adduct formation was up to 2.1-fold higher than in incubations with 
cytosols from control animals. This increase corresponded to an increase in protein level and 
enzymatic activity of NQO1. Incubations of 3-ABA with microsomes of 3-NBA-treated rats led to 
up to a 5-fold increase in DNA adduct formation relative to controls. The stimulation of DNA 
adduct formation correlated with the potential of 3-NBA to induce protein expression and activity 
of CYP1A1. These results demonstrate that 3-NBA is capable to induce NQO1 and CYP1A1 in 
lungs and kidney of rats thereby enhancing its own genotoxic and carcinogenic potential.  
________________________________________________________________________________ 
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1. Introduction 
Lung cancer is the most common malignant disease worldwide and is the major cause of death 
from cancer. Although tobacco smoking is the overwhelming cause of lung cancer, vehicular 
exhaust and ambient air pollution are also implicated as causative factors (IARC, 1989; 
Environmental Protection Agency, 2002; Vineis et al., 2004; Grashick et al., 2004). Nitro-aromatic 
compounds are widely distributed environmental pollutants found in exhaust from diesel and 
gasoline engines and on the surface of ambient air particulate matter. The increased lung cancer risk 
after exposure to these environmental sources and the detection of nitro-aromatics in the lungs of 
non-smokers with lung cancer has led to considerable interest in assessing their potential cancer risk 
(IARC, 1989; Environmental Protection Agency, 2002; Vineis et al., 2004; Grashick et al., 2004). 
The nitroaromatic 3-nitrobenzanthrone (3-nitro-7H-benz[de]anthracen-7-one, 3-NBA, Fig. 1) 
occurs in diesel exhaust and in airborne particulate matter (Enya et al., 1997; Seidel et al., 2002; 
Nagy et al., 2005; Arlt, 2005). The main metabolite of 3-NBA, 3-aminobenzanthrone (3-ABA, Fig. 
1) (Hansen et al., 2007; Svobodová et al., 2007), has been found in urine samples of salt mine 
workers occupationally exposed to diesel emissions (Seidel et al., 2002), demonstrating human 
exposure to 3-NBA. 3-NBA is carcinogenic in rats, causing lung tumours after intratracheal 
instillation (Nagy et al., 2005). It is also an exceptionally potent mutagen in the Ames Salmonella 
typhimurium assay, scoring more than 6 million revertants per nanomole in strain YG1024 
overexpressing bacterial nitroreductase and O-acetyltransferase (Enya et al., 1997). 3-NBA has also 
been shown to be genotoxic in several other short-term tests and in the transgenic Muta Mouse 
assay (Arlt et al., 2004a; 2004c). Its genotoxicity has been further documented by the detection of 
specific DNA adducts formed in vitro as well as in vivo in rodents in various tissues (Arlt et al., 
2001; 2002; 2003a; b; c; 2004a; c; 2005; 2006b; Bieler et al., 1999; 2005; 2007).  
In the liver, most of the metabolic activation of 3-NBA in vitro is attributable to human and rat 
cytosolic NAD(P)H:quinone oxidoreductase (NQO1), while human N,O-acetyltransferase (NAT), 
NAT2, followed by NAT1, sulfotransferase (SULT), SULT1A1 and, to a lesser extent, SULT1A2 
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are the major activating phase II enzymes (Arlt et al., 2005; Stiborová et al., 2006). Hepatic 
microsomal NADPH:cytochrome P450 (CYP) reductase is also effective in the activation of 3-NBA 
(Arlt et al., 2003c), but in mice, 3-NBA is predominantly activated by NQO1 rather than 
NADPH:CYP reductase (Arlt et al., 2005) (Fig. 1). The enzymes that activate 3-NBA in the lung, 
the target organ for its carcinogenicity (Nagy et al., 2005), and in other extra-hepatic tissues have 
not yet been identified.  
CYP1A1 and 1A2 (CYP1A1/2) are essential for the oxidative activation of 3-ABA in human 
and rat livers forming the same DNA adducts that are formed in vivo by 3-ABA or 3-NBA (Arlt et 
al., 2004b). However, other organs also have the metabolic capacity to activate 3-ABA to form 
DNA adducts, independent of the CYP-mediated oxidation in the liver (Arlt et al., 2006a). Previous 
results indicate that besides CYP enzymes expressed in several extra-hepatic tissues, peroxidases 
might play a role in the oxidative activation of 3-ABA (Arlt et al., 2006a).  In in-vitro experiments, 
mammalian prostaglandin H synthase (cyclooxygenase, COX), lactoperoxidase (LPO) and 
myeloperoxidase (MPO) were found to be effective in activating 3-ABA (Arlt et al., 2006a) (Fig. 
1). However, in extra-hepatic tissues the actual role of CYPs and peroxidases in the metabolic 
activation of 3-ABA and their relative contributions to such activation remain to be investigated. 
The potential of 3-NBA to influence the expression and activities of enzymes involved in its own 
activation and that of its metabolite 3-ABA also requires examination. Thus, although we recently 
found that 3-NBA induces the major enzymes activating it and its metabolite 3-ABA in rat livers 
(Stiborová et al., 2006), its potential to induce such enzymes in extra-hepatic organs has not yet 
been investigated. 
The present study was undertaken to determine the capability of cytosols and microsomes 
isolated from two rat organs; the lung, the target organ for 3-NBA carcinogenicity, and the kidney, 
an important organ for excretion of xenobiotics, to activate 3-NBA and 3-ABA. A further aim was 
to identify enzymes involved in DNA adduct formation by 3-NBA and 3-ABA in rat lung and 
kidney and to evaluate whether treatment by 3-NBA induces these enzymes. 
 6
2. Material and Methods 
2.1. Chemicals  
NADPH, hypoxanthine (HX), dicoumarol, allopurinol, deoxyadenosine (dA) 3’-monophospate, 
deoxyguanosine (dG) 3’-monophosphate, acetyl coenzyme A (acetyl-CoA) 3’-phosphoadenosine-
5’-phosphosulfate (PAPS), menadione (2-methyl-1,4-naphthoquinone) and calf thymus DNA were 
from Sigma Chemical Co (St Louis, MO, USA); Sudan I from BDH (Poole, UK); 7-ethoxyresorufin 
from Fluka Chemie AG (Buchs, Switzerland). Enzymes and chemicals for the 32P-postlabelling 
assay were obtained from sources described (Phillips and Arlt, 2007). All these and other chemicals 
were reagent grade or better. 
2.2. Synthesis of 3-NBA and 3-ABA 
 3-NBA and 3-ABA were synthesized as described (Arlt et al., 2003a) and their authenticity was 
confirmed by UV spectroscopy, electrospray mass spectra and high field proton NMR spectroscopy.  
2.3. Animal experiments 
 The study was conducted in accordance with the Regulations for the Care and Use of 
Laboratory Animals (311/1997, Ministry of Agriculture, Czech Republic), which is in compliance 
with Declaration of Helsinki. Male Wistar rats (100-125 g, n=3 per group) were treated with a 
single dose of 0.4, 4 or 40 mg/kg bw of 3-NBA by intraperitoneal injection. 3-NBA was dissolved 
in sunflower oil at a concentration of 0.4 or 4 mg/ml. Three control animals received an equal 
volume of oil only. Rats were placed in cages in temperature and humidity controlled rooms. 
Standardised diet and water were provided ad libitum. The animals were killed 24 hours after 
treatment by cervical dislocation. Lungs and kidneys were removed immediately after death and 
used for isolation of mRNA and for preparation of microsomal and cytosolic fractions.  
2.4. Preparation of microsomal and cytosolic fractions  
Microsomal and cytosolic fractions were isolated from the lungs and kidneys of rats, either 
uninduced or pretreated with 3-NBA (see above) as described (Stiborová et al., 2003). Both 
subcellular preparations were analysed for the presence of 3-NBA using the HPLC on a CC 250/4 
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Nucleosil, 100-5 C18 HD column (Macherey-Nagel, 4 x 250 mm) preceded by a C-18 guard 
column.  Eluent was 70% methanol in water, at a flow rate of 0.6 ml min-1, and detection was at 254 
nm. The standard of 3-NBA eluted with a retention time of 8.2 min. No 3-NBA was detectable in 
microsomal and cytosolic fractions from rats that had been pretreated with this compound. 
2.5. Cytosolic incubations  
The deaerated and argon-purged incubation mixtures, in a final volume of 750 µl, consisted of 
50 mM Tris-HCl buffer (pH 7.4), containing 0.2% Tween 20, cofactors for cytosolic enzymes (1 
mM NADPH, NADH or HX; 2 mM acetyl-CoA; 100 µM PAPS), pooled lung and kidney cytosolic 
sample from 3 rats, treated either with vehicle (control) or with 40 mg/kg bw of 3-NBA (1 mg of 
cytosolic protein), 30 µM 3-NBA (dissolved in 7.5 µl dimethylsulfoxide) and 0.5 mg of calf thymus 
DNA (2 mM dNp). The reaction was initiated by adding 3-NBA. Incubations with rat cytosols were 
carried out at 37°C for 3 hr; the cytosol-mediated 3-NBA-derived DNA adduct formation was 
found to be linear up to 4 hr (Arlt et al., 2005). Control incubations were carried out either (i) 
without activating system (cytosol), (ii) without cofactors (NADPH, NADH, HX), (iii) without 
DNA or (iv) without 3-NBA. After extraction with ethyl acetate, DNA was isolated from the 
residual water phase by the phenol/chloroform extraction method as described (Arlt et al., 2005).  
Incubations used to evaluate the activation of 3-ABA by peroxidases in rat pulmonary and renal 
cytosolic samples contained, in a final volume of 750 µl, 50 mM Tris-HCl buffer (pH 7.4), 
containing 0.2% Tween 20, 100 µM 3-ABA (dissolved in 7.5 µl dimethylsulfoxide), 0.5 mg of calf 
thymus DNA and 200 µM H2O2. 
2.6. Cytosolic inhibition studies 
Dicoumarol and allopurinol were used to inhibit NQO1 and xanthine oxidase (XO), respectively, in 
rat pulmonary and renal cytosolic fractions (Watanabe et al., 1997; Ritter et al., 2000). Inhibitors 
dissolved in 7.5 µl of methanol, to yield final concentrations of 10 µM, were added to the 
incubation mixtures as reported previously (Arlt et al., 2005). An equal volume of methanol was 
added to the control incubations. 
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2.7. Microsomal incubations 
 Incubation mixtures, in a final volume of 750 µl, consisted of 50 mM potassium phosphate buffer 
(pH 7.4), 1 mM NADPH or 0.1 mM arachidonic acid, pooled pulmonary and renal microsomal 
sample from 3 rats, either control or treated with 40 mg/kg bw of 3-NBA (0.5 mg of microsomal 
protein), 100 µM 3-ABA or 3-NBA (dissolved in 7.5 µl dimethylsulfoxide) and 0.5 mg of calf 
thymus DNA. The reaction was initiated by adding 3-ABA or 3-NBA and were carried out at 37°C 
for 2 hr; the microsomal-mediated 3-NBA (3-ABA)-derived DNA adduct formation was found to 
be linear up to 3 hr (Arlt et al., 2003c; 2004b). Control incubations were carried out either (i) 
without activating system (microsomes), (ii) with activating system and 3-ABA, but without DNA 
or (iii) with activating system and DNA but without 3-ABA. After the incubation and extraction 
with ethyl acetate, DNA was isolated from the residual water phase by the phenol/chloroform 
extraction method as described (Arlt et al., 2004b).  
2.8. Microsomal inhibition studies 
 α-Naphthoflavone (α-NF) (Sigma), which inhibits CYP1A (Rendic and DiCarlo, 1997; Stiborová 
et al., 2005b), and indomethacin (Sigma), which inhibits COX (Eling et al., 1990), were used to 
inhibit the activation of 3-ABA by rat pulmonary and renal microsomes. Inhibitors were dissolved 
in 7.5 µl of methanol and were added to the incubation mixtures to yield final concentrations of 100 
µM. The incubation mixtures containing the inhibitors were then incubated at 37°C for 10 min with 
NADPH or arachidonic acid prior to adding 3-ABA and then for a further 120 min at 37°C. An 
equal volume of methanol alone was added to the control incubations. 
2.9. 32P-Postlabelling analysis and HPLC analysis of 32P-labelled 3’,5’-deoxyribonucleoside 
bisphosphate adducts 
 
32P-Postlabelling analysis using butanol extraction, and thin layer chromatography (TLC) and 
HPLC were performed as described (Arlt et al., 2006b). Enrichment by butanol extraction has been 
shown to yield more adduct spots and a better recovery of 3-NBA (3-ABA)-derived DNA adducts 
than using enrichment by nuclease P1 digestion (Arlt et al., 2001; 2004b). DNA adduct spots were 
 9
numbered as reported (Arlt et al., 2006b). As reference compounds deoxyadenosine (dAp) and 
deoxyguanosine (dGp) 3’-monophosphates (4 µmol/ml) (Sigma) were incubated with 3-NBA (300 
µM) activated by XO (1 U/ml) (Sigma) in the presence of HX and analysed as described previously 
(Arlt et al., 2001). DNA adduct standard samples of 3-NBA, 2-(2’-deoxyadenosin-N6-yl)-3-
aminobenzanthrone-3’-phosphate (dA3’p-N6-ABA), N-(2’-deoxyguanosin-N2-yl)-3-
aminobenzanthrone-3’-phosphate (dG3’p-N2-ABA) and N-(2’-deoxyguanosin-8-yl)-3-
aminobenzanthrone-3’-phosphate (dG3’p-C8-N-ABA), were prepared by reacting N-acetoxy-3-
aminobenzanthrone with dAp or dGp and analysed as described recently (Arlt et al., 2006b).   
2.10. Isolation of CYP1A1 
Recombinant rat CYP1A1 protein was purified to homogeneity from membranes of Escherichia 
coli transfected with a modified CYP1A1 cDNA (Stiborová et al., 2002), in the laboratory of H. W. 
Strobel (University of Texas, Medical School of Houston, Texas, USA) by P. Hodek (Charles 
University, Prague, Czech Republic).  
2.11. Preparation of antibodies  
Leghorn chicken were immunised subcutaneously three times a week with rat recombinant 
CYP1A1  and  human recombinant NQO1 (Sigma) antigens (0.1 mg/animal) emulsified in 
complete Freund’s adjuvant for the first injection and in incomplete adjuvant for boosters. 
Immunoglobulin fraction was purified from pooled egg yolks using fractionation by polyethylene 
glycol 6000 (Stiborová et al., 2002). 
2.12. Estimation of CYP1A1 and NQO1 protein content in microsomes and cytosols of rat lung and 
kidney  
Immunoquantitation of rat pulmonary and renal microsomal CYP1A1 and of cytosolic NQO1 
was done by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis. Samples 
containing 75 µg microsomal or cytosolic proteins were subjected to electrophoresis on SDS/10% 
polyacrylamide gels (Stiborová et al., 2002; 2005b, 2006). After migration, proteins were 
transferred onto polyvinylidene difluoride membranes. Rat CYP1A1 and NQO1 proteins were 
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probed with the chicken polyclonal antibodies as reported elsewhere (Stiborová et al., 2002; 2005b; 
2006). The antibodies against rat recombinant CYP1A1 and human NQO1 recognise these enzymes 
in rat pulmonary and renal microsomes as one protein band. Rat recombinant CYP1A1 (in 
SupersomesTM, Gentest Corp., Woburn, MA, USA) and human recombinant NQO1 (Sigma 
Chemical Co, St Louis, MO, USA) were used as positive controls to identify the bands of CYP1A1 
in microsomes and NQO1 in cytosols. The antigen-antibody complex was visualised with an 
alkaline phosphatase-conjugated rabbit anti-chicken IgG antibody and 5-bromo-4-chloro-3-
indolylphosphate/nitrobluetetrazolium as chromogenic substrate (Stiborová et al., 2002; 2005b; 
2006).   
2.13. CYP1A1 and NQO1 enzyme activity assays  
The microsomal samples were characterised for CYP1A1 activity using 7-ethoxyresorufin O-
deethylation (EROD) activity and the oxidation of Sudan I (Stiborová et al., 2002; 2005b). The 
cytosolic samples were characterised for NQO1 activity, using menadione (2-methyl-1,4-
naphthoquinone) as a substrate (Stiborová et al., 2003). NQO1 activity was determined by 
following the oxidation of NADPH spectrophotometrically at 340 nm. The standard assay system 
contained 25 mM Tris-HCl (pH 7.4), 0.2% Tween 20, 0.07% bovine serum albumin, 400 mM 
NADPH and 100 mM menadione dissolved in methanol.  
2.14. CYP1A1 and NQO1 mRNA content in rat lungs and kidneys  
Total RNA was isolated from frozen lungs and kidneys of three untreated rats and three rats 
pretreated with 40 mg/kg body weight of 3-NBA or 3-ABA using Trizol Reagent (Invitrogen, 
Carlsbad, CA, USA) according to the procedure supplied by the manufacturer. The quality of 
isolated RNA was verified by horizontal agarose gel electrophoresis, RNA quantity was assessed by 
UV-VIS spectrophotometry on a Carry 300 spectrophotometer (Varian, Palo Alto, CA, USA). RNA 
samples (1 µg) were reversely transcribed using 200 U of reverse transcriptase per sample with 
random hexamer primers utilising RevertAidTM First Strand cDNA Synthesis Kit (MBI Fermentas, 
Vilnius, Lithuania) according to the manufacturer's instructions. The prepared cDNA was used for 
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real-time (RT) polymerase chain reaction (PCR) performed in RotorGene 2000 (Corbett Research, 
Sydney, Australia) under the following cycling conditions: incubation at 50ºC for 2 min and initial 
denaturation at 95ºC for 10 min, then 50 cycles of denaturation at 95ºC for 15 s and annealing at 
60ºC for 1 min. Gain was set to 7 and fluorescence was acquired after elongation step. The PCR 
reaction mixtures (20 µl) contained 9 µl cDNA diluted 10-times in Milli-Q ultrapure water (Biocel 
A10, Millipore, Billerica, MA, USA), 10 µl TaqMan Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA) and 1 µl TaqMan Gene Expression Assay Mix (commercially 
available unlabelled PCR primers and FAMTM dye-labelled probe for rat CYP1A1 or NQO1 as 
target genes and β-actin as reference internal standard gene). Each sample was analysed in two 
parallel aliquots. Negative controls had the same compositions as samples but cDNA was omitted 
from the mixture. Data were analysed by the program RotorGene v6 (Corbett Research, Sydney, 
Australia) and evaluated by comparative cycle threshold (cT) method for relative quantitation of 
gene expression. Cycle thresholds, at which a significant increase in fluorescence signal was 
detected, were measured for each sample. Then ∆∆cT was evaluated according to following 
equations: ∆cT = cT (target) - cT (internal standard), ∆∆cT = ∆cTtreated - ∆cTcontrol, where ∆cTtreated is 
∆cT for treated rats and ∆cTcontrol is ∆cT for untreated rats. ∆cT is positive if the target is expressed at 
a lower level than the internal standard (β-actin), and negative if expressed at a higher level. The 
induction of mRNA expression of studied target genes in pretreated animals was evaluated as 2-
(∆∆cT)
. 
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3. Results 
3.1. Activation of 3-NBA by rat pulmonary and renal cytosols and microsomes  
DNA adduct formation in calf thymus DNA measured by thin-layer 32P-postlabelling was used 
to investigate the metabolic activation of 3-NBA by cytosolic fractions. Rat pulmonary and renal 
cytosolic samples were capable of reductively activating 3-NBA to species forming DNA adducts 
(see Fig. 2A for the lung cytosol). The DNA adduct pattern generated by 3-NBA consisted of a 
cluster of up to five adducts (spots 1−5 in Figure 2) essentially identical to that observed in vivo in 
rats and mice treated with 3-NBA (Arlt et al., 2001; 2003b; 2005; Bieler et al., 2005; 2006), and in 
in-vitro incubations using human and rat hepatic cytosols (Arlt et al., 2005) or microsomes (Arlt et 
al., 2003c). Thin-layer chromatograms of 32P-labelled DNA from control incubations carried out in 
parallel without cytosol, without DNA, or without 3-NBA were devoid of adduct spots in the region 
of interest (data not shown). Cochromatographic analysis of individual spots on HPLC confirmed 
that adduct spots 1−5 that are formed with rat pulmonary and renal cytosols are derived from 3-
NBA by nitroreduction (data not shown). Three of these adducts were identified as 2-(2’-
deoxyadenosin-N6-yl)-3-aminobenzanthrone (dA-N6-ABA; spot 1), N-(2’-deoxyguanosin-N2-yl)-3-
aminobenzanthrone (dG-N2-ABA; spot 3) and N-(2’-deoxyguanosin-8-yl)-3-aminobenzanthrone 
(dG-C8-N-ABA; spots 4 and 5).  
We therefore analysed which cytosolic reductase is responsible for 3-NBA-DNA-adduct 
formation. Cytosolic fractions from both organs were capable of activating 3-NBA to form DNA 
adducts, even without addition of cofactors for cytosolic reductases. With kidney cytosol, up to 4-
times higher adduct levels were generated than with lung cytosol. As shown in Figure 3A the 
formation of 3-NBA-DNA adducts by lung cytosol was stimulated by NADPH and NADH, the 
cofactors of NQO1, (Ross et al., 2000), and the cofactor of XO, HX (Swaminathan and Hatcher, 
1986). Using renal cytosol, 3-NBA-DNA adduct formation increased 2.7-fold after the addition of 
NADPH or NADH, while no increase was detected after addition of HX (Fig 3B). Hence, NQO1 
and XO reductively activate 3-NBA in pulmonary cytosol, although XO seems to play a minor role 
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in this organ and does not seem to be important in renal cytosol. This finding is also supported by 
the fact that 3-NBA-DNA adduct formation in cytosols of both tissues was markedly decreased by 
dicoumarol, an inhibitor of NQO1 (Watanabe et al., 1997; Ritter et al., 2000), whereas allopurinol, 
an inhibitor of XO (Watanabe et al., 1997; Ritter et al., 2000), showed no effect (Table 1).  
The influence of SULTs and NATs on the activation of 3-NBA in pulmonary and renal cytosols 
was then investigated by adding either PAPS, the cofactor of SULTs (Glatt et al., 2001), or acetyl-
CoA, the cofactor of NATs (King et al., 2000), into the incubation mixtures. The addition of PAPS 
and acetyl-CoA resulted in a 2.5- and 29.7-fold increase in the levels of 3-NBA adducts in 
uninduced cytosols, respectively, over the activity with NADPH alone (Fig. 4 and Supporting Table 
S1). Thus, SULTs and mainly NATs strongly contribute to the metabolic activation of 3-NBA in rat 
pulmonary and renal cytosols. 
In further experiments we studied the formation of adducts in calf thymus DNA by 3-NBA 
incubated with cytosols from rats pretreated with 3-NBA (40 mg/kg bw). These pulmonary and 
renal cytosolic samples were more effective in formation of 3-NBA-DNA adducts in the presence 
of NADPH, than the pulmonary and renal cytosols of untreated (control) rats (Fig. 4 and Supporting 
Table S1). Formation of 3-NBA-DNA adducts was up to 2.1-fold higher in incubations with 
cytosols of rats treated with 3-NBA relative to those of control rats (Fig. 4). Addition of PAPS and 
acetyl-CoA to the incubations with induced cytosols had essentially the same stimulatory effects on 
3-NBA adduct formation as in control cytosols; a 2- and 29.6-fold increase, respectively, was 
observed in comparison to the activity using NADPH (Fig. 4 and Supporting Table S1).   
Comparison of the efficiencies of microsomes isolated from lungs and kidneys of rats either 
uninduced or pretreated with 3-NBA to activate this carcinogen was also performed. No 3-NBA-
derived DNA adducts were detectable after incubating 3-NBA with any of these pulmonary or renal 
microsomes and NADPH (data not shown). Hence, it seems that microsomal NADPH:CYP 
reductase and/or CYP are not involved in 3-NBA activation in these organs. 
3.2. Activation of 3-ABA by rat pulmonary and renal microsomes and cytosols 
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In contrast to 3-NBA, 3-ABA was activated by lung and kidney microsomes. Because CYPs 
and peroxidases were found to activate 3-ABA (Arlt et al., 2004b; 2006a), we investigated the 
modulation of 3-ABA-derived DNA adduct formation by cofactors and selective enzyme inhibitors. 
In the presence of NADPH, a cofactor of CYP-dependent enzyme systems, all pulmonary and renal 
microsomes were capable of oxidising 3-ABA to form DNA adducts.  Microsomal activation of 3-
ABA generated a pattern of DNA adducts consisting of a cluster of five adducts (see spots 1-5 in 
Figure 2 for the lung microsomes), identical to those formed by 3-ABA and 3-NBA in vitro and in 
vivo (Arlt et al., 2001; 2002; 2003a; b; c; 2004b; c; 2005; 2006a; b; Bieler et al., 2005). Arachidonic 
acid, a cofactor for COX-dependent oxidation (Eling et al., 1990; Stiborová et al., 2005a; 2007; Arlt 
et al., 2006a), also mediated formation of DNA adducts, but was less effective than NADPH (Fig. 
5). In the presence of NADPH, lung and kidney microsomes from rats treated with 3-NBA (40 
mg/kg bw) exhibited 5- and 3.4-fold higher efficiencies to activate 3-ABA, than microsomes from 
untreated rats, respectively (Fig. 5 and Supporting Table S2). Microsomes from rats treated with 3-
NBA were also more effective in 3-ABA activation in the presence of arachidonic acid, but only 
1.5-fold higher levels of DNA adducts were detected (Fig. 5 and Supporting Table S2). 
Chromatograms of DNA digests from control incubations carried out in parallel without 
microsomes, without NADPH, without arachidonic acid, without DNA, or without 3-ABA were all 
devoid of adduct spots in the region of interest (data not shown). 
Addition of α-NF, an inhibitor of CYP1A1 (Rendic and DiCarlo, 1997), decreased the levels of 
DNA adducts generated by pulmonary and renal microsomes, while indomethacin, an inhibitor of 
COX (Eling et al., 1990), was less effective (Fig. 5 and Supporting Table S2). The inhibitory effect 
of α-NF in pulmonary and renal microsomes from pretreated rats was even higher than in 
microsomes of uninduced rats (Fig. 5 and Supporting Table S2). These results point to CYP1A1 
having a major role in DNA adduct formation by 3-ABA in rat lungs and kidneys. Additionally, 
they show that treating rats with 3-NBA increases the relative contribution of this enzyme to 3-
ABA activation in both organs. 
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In the presence of hydrogen peroxide, a cofactor for peroxidases, the pulmonary and renal 
cytosols from uninduced rats and animals treated with 3-NBA were capable of activating 3-ABA to 
form DNA adducts. In contrast to pulmonary cytosol, by which five 3-ABA-DNA adducts (spots 1-
5 in Figure 2) were generated, in the renal cytosolic activation system, only four 3-ABA-DNA 
adducts (spots 1-4 in Figure 2) were detected. Treatment of rats with 3-NBA slightly stimulated 
(1.3-fold) the formation of 3-ABA-DNA adducts in cytosols of both organs (Fig 6 and Supporting 
Table S3). No adducts were detectable in controls without cytosols, without 3-ABA (data not 
shown), or without hydrogen peroxide (Fig 6 and Supporting Table S3). 
3.3. The effect of 3-NBA pretreatment on expression of enzymes activating 3-NBA and 3-ABA  
Because NQO1 and CYP1A1 were found to be the essential enzymes activating 3-NBA and 3-
ABA with subcellular fractions from rat lungs and kidneys (present paper) and from rat and human 
livers (Arlt et al., 2004b; 2005), we evaluated whether treating rats with 3-NBA influences 
expression of these enzymes. The induction of these enzymes has already been found in the liver of 
rats treated with 3-NBA (Stiborová et al., 2006). In the present study, Western blots with chicken 
polyclonal antibodies raised against NQO1 and CYP1A1 showed that the expression of both 
enzymes was also induced in rat lung and kidney by 3-NBA (Fig. 7). The efficiency of 3-NBA to 
induce CYP1A1 expression was higher in lung than in kidney (7.4-fold versus 3.4-fold at 40 mg/kg) 
(Fig. 7). EROD activity and oxidation of Sudan I, as markers of CYP1A1 activity (Stiborová et al., 
2002; 2005b), were increased in both organs of rats treated with 3-NBA (Table 2). Again, the 
induction in lung was higher than in kidney, although control enzyme activity in lung was only half 
of that in kidney. 
The levels of renal and pulmonary NQO1 protein were enhanced by pretreating rats with 3-
NBA (40 mg/kg bw), by 2.3- and 1.4-fold, respectively (Fig. 7). The increase in NQO1 activities in 
cytosols depended on the administered dose and correlated with the protein expression (Table 3 and 
Fig. 7). Up to a 2.5-fold increase in NQO1 activity measured with menadione as a substrate was 
found in tissues of rats treated with 3-NBA (Table 3).  
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Besides the evaluation of the effects of 3-NBA on protein levels and enzyme activities of 
CYP1A1 and NQO1, modulation of their mRNA expression by the compound was also 
investigated.  The relative amounts of CYP1A1 and NQO1 mRNA were measured by RT-PCR 
analysis. As shown in Table 4, treatment of rats with 40 mg/kg bw of 3-NBA induced mRNA levels 
of CYP1A1 and NQO1 up to 3.9- and 1.4-fold, respectively, in the tissues studied.  
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4. Discussion 
The present study has increased our knowledge on the potential of cytosolic and microsomal 
fractions of rat lungs and kidneys to activate 3-NBA and 3-ABA, and on the enzymes participating 
in their bioactivation. The rat was used as an experimental model on the basis that the same 
enzymes activate 3-NBA and 3-ABA in livers of both species (Arlt et al., 2003a, c, 2004b, 2005, 
2006a; Stiborová et al., 2006). Therefore, the results should provide some indication of what might 
occur in extra-hepatic tissues of humans exposed to this pollutant.  
DNA adducts formed during 3-NBA and 3-ABA activation by the cytosolic and microsomal 
fractions are identical to those formed in vivo in rats and mice treated with 3-NBA or 3-ABA (Arlt 
et al., 2001; 2003b; 2004; 2005; 2006a; Bieler et al., 2005; 2007), and in in-vitro incubations using 
human and rat hepatic cytosols (Arlt et al., 2005) or microsomes (Arlt et al., 2003c; 2004b). 
However, cytosols or microsomes of rat livers (Stiborová et al., 2006) were up to an order of 
magnitude more effective in activation of both compounds than those of lung and kidney.  
In the case of 3-NBA, rat cytosolic reductase(s) of both organs studied are responsible for its 
reductive activation to DNA-binding products, while microsomal enzymes were ineffective under 
conditions used in the experiments. These results are consistent with those found in vivo; 3-NBA is 
predominantly activated by cytosolic nitroreductases rather than microsomal NADPH:CYP 
reductase (Arlt et al., 2005). The stimulation of 3-NBA-DNA adduct formation in rat pulmonary 
and renal cytosolic samples by NADPH suggested the participation of NQO1 in the reductive 
bioactivation of 3-NBA. Inhibition of DNA adduct formation by dicoumarol, an inhibitor of NQO1, 
provided additional evidence for the major role of NQO1. Hence, the same cytosolic reductase, 
NQO1, functions as the most effective enzyme activating 3-NBA both in the extra-hepatic organs, 
lung and kidney, and in the liver of rats (Arlt et al., 2005). Similarly, NQO1 is the most effective 
enzyme reductively activating 3-NBA in human hepatic cytosol (Arlt et al., 2005). Compared to 
NQO1, XO had no impact in kidney cytosol on the activation of 3-NBA to form DNA adducts. 
However, a low, but significant, stimulatory effect of a cofactor of this enzyme, HX, was found in 
 18
pulmonary cytosols. This is consistent with a previous observation (Borlak et al., 2000) that the 
reductive metabolism of 3-NBA to 3-ABA in rat alveolar type II cells was mediated, at least in part, 
by XO.  In addition, our earlier data had shown that XO (isolated from buttermilk) was an effective 
activator of 3-NBA (Bieler et al., 1999), but only at unphysiological levels of enzyme.   
In the present study we have demonstrated that pulmonary and renal NATs and SULTs also 
participate in the bioactivation of 3-NBA leading to DNA adducts. Addition of a cofactor for 
SULT, PAPS, increased 3-NBA-DNA-adduct levels approximately 2-fold in cytosols from both 
organs. A cofactor of NAT, acetyl-CoA, was even more effective in stimulating 3-NBA-DNA 
adduct formation; an order of magnitude higher levels of DNA adducts than without acetyl-CoA 
were detected. The importance of NATs and SULTs for 3-NBA activation was previously found in 
rat and human livers (Arlt et al., 2005; Stiborová et al., 2006) and in genetically engineered V79 
cells expressing human NAT1, NAT2, SULT1A1 or SULT1A2 (Arlt et al., 2002; 2003a). 
Moreover, in these V79 cells, 3-NBA induced a dose-dependent increase in the mutation frequency 
at the hprt locus (H.R. Glatt, personal communication), indicating that the expression of NATs and 
SULTs contributes to the mutagenic potential of 3-NBA in mammalian systems.  
In the case of 3-ABA, both microsomal and cytosolic enzymes of rat lung and kidney are 
capable of its activation to DNA binding species forming up to five DNA adducts. Stimulation of 3-
ABA-DNA adduct formation by NADPH, a cofactor of CYP-dependent enzyme systems, and its 
inhibition by α-NF, an inhibitor of CYP1A1, indicate the predominant role of this microsomal 
enzyme in 3-ABA activation. The formation of 3-ABA-DNA adducts with microsomes is also 
mediated by arachidonic acid, a cofactor of COX, and in cytosols also by H2O2, a cofactor of 
cytosolic peroxidases. This finding supports our previous data on the role of peroxidases in the 
activation of 3-ABA (Arlt et al., 2006a).  
Inter-individual variations in susceptibility and variations in drug-metabolizing enzyme 
activities in target tissues appear to be important determinants of cancer risk (Smith et al., 1995; 
Perera, 1997). It is known that both NQO1 and CYP1A1 are expressed not only in lungs and 
 19
kidneys of rats, but also in these tissues in humans (Rendic and DiCarlo, 1997; Ross et al., 2000). 
Likewise, NATs and SULTs are expressed in several human organs, including the respiratory tract 
(Willey et al., 1996; Mace et al., 1998; Richard et al., 2001). NAT1 mRNAs have been detected in 
human bronchial mucosa and peripheral lung tissue and NAT2 expression has been detected in the 
bronchus (Mace et al., 1998). Human bronchial epithelial cells and alveolar macrophages belong to 
the primary defence system against inhaled compounds and SULT1A1 is expressed in these cells 
(Willey et al., 1996; Richard et al., 2001). Therefore, NQO1, CYP1A1, NAT and SULT expression 
in the respiratory system could contribute significantly and specifically to the metabolic activation 
of 3-NBA and/or 3-ABA in the lung, thereby mediating 3-NBA carcinogenicity in this organ.  
Expression levels and activities of NQO1, CYP1A1, NATs and SULTs differ considerably 
among individuals, because the enzymes are influenced by several factors, including smoking, 
drugs, environmental chemicals and genetic polymorphisms (Rendic and DiCarlo, 1997; Schulz et 
al., 1997; Chen et al., 1998). So far two polymorphisms in the human NQO1 gene have been found 
in the general population, one of them being associated with an increased risk of urothelial tumours 
(Schulz et al., 1997) and pediatric leukaemia (Wiemels et al., 1999). The polymorphic expression of 
CYP1A1 has been attributed to altered expression of the aryl hydrocarbon (Ah) receptor, the 
transcription factor that modulates its regulation, or the Ah receptor nuclear translocator (Arnt) 
protein, its associated transcription factor (Rendic and DiCarlo, 1997; Hukkanen et al., 2002; 
Dickins, 2004). Moreover, the CYP1A1 gene is genetically polymorphic (Rendic and DiCarlo, 
1997; Hukkanen et al., 2002).  So far, CYP1A1*2A, CYP1A1*2B and CYP1A1*4 polymophisms  
have been found that might be associated with lung, oesophageal or breast cancer and with acute 
myeloid leukaemia (D’Alo et al., 2004; Yang et al., 2005; Li et al., 2004; 2005). The human NAT1 
and NAT2 genes are also genetically polymorphic, resulting in different activities of the gene 
product that segregate individuals into slow and rapid acetylator phenotypes (Hein et al., 2000). 
SULT1A1 and SULT1A2 are also polymorphic in humans (Raftogianis et al., 1999; Engelke et al., 
2000) and are associated with increased cancer risk including lung cancer (Wang et al., 2002). 
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Thus, genetic polymorphisms in CYP1A1, NQO1, NAT and SULT genes could be important 
determinants of a possible lung cancer risk from 3-NBA.  
Human and rat CYP1A1 is induced by many compounds, e.g. by planar aromatic compounds 
binding to the Ah receptor, e.g. 2,3,7,8-tetrachlorodibenzo[1,4]dioxine (TCDD) (Drahushuk et al., 
1998), and by polycyclic hydrocarbons present in cigarette smoke (Rendic and DiCarlo, 1997; 
Hukkanen et al., 2002). NQO1 is inducible by a variety of agents with different mechanisms of 
action (see Ross et al., 2000 for a review). Among NQO1 inducers also tumour promoters and 
hydrogen peroxide have been reported (Prestera et al., 1993; Li and Jaiswal, 1994; Jaiswal, 1994).  
Human exposure to 3-NBA is thought to occur primarily via the respiratory tract, and inhaled 
particles, e.g. derived from diesel emissions, are able to generate reactive oxygen species like 
hydrogen peroxide (Knaapen et al., 2004). Reactive oxygen species including hydrogen peroxide 
were even found to be generated by either 3-NBA itself or its metabolite 3-ABA in human A549 
lung epithelial cells (Hansen et al., 2007). Hence, induction of NQO1 by hydrogen peroxide formed 
after exposure to particulate matter and 3-NBA might be a contributing risk factor, increasing 3-
NBA activation and its binding to DNA, thereby enhancing its genotoxic potential. In addition, 
hydrogen peroxide produced by 3-NBA metabolite, N-hydroxy-3-aminobenzanthrone, was found to 
cause oxidative damage to DNA in human leukemia cells (Murata et al., 2006). Generation of 
hydrogen peroxide in the respiratory tract is also essential for peroxidases expressed in the lung (i.e. 
MPO and/or COX), which activate 3-ABA (Arlt et al., 2006a; present paper). In this context, it is 
noteworthy that 3-ABA is the major metabolite of 3-NBA in human fetal bronchial, human A549 
lung epithelial, rat alveolar type II, rat epithelial bronchial, and rat mesenchymal lung cells (Borlak 
et al., 2000; Hansen et al., 2007).  Furthermore, hydrogen peroxide required for peroxidase-
mediated 3-ABA oxidation can also be supplied by XO, which as we show here, also contributes to 
the bioactivation of 3-NBA in lung cells. 
In the present study, we have shown that 3-NBA acts as an inducer of the enzymes responsible 
for its own metabolic activation (NQO1) and its metabolite 3-ABA (CYP1A1). The expression of 
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NQO1 and CYP1A1 mRNAs and proteins was induced by 3-NBA in lungs and kidneys of rats 
treated i.p. with a single dose of 0.4, 4 or 40 mg/kg bw of 3-NBA. This induction leads to an 
increase in the activities of these enzymes and in their potential to activate 3-NBA in cytosols 
(NQO1) and 3-ABA in microsomes (CYP1A1) of both organs to species forming DNA adducts, 
thereby enhancing the first step of their activation. The specific mechanism(s) of induction of 
NQO1 and CYP1A1 by 3-NBA remain(s) to be determined.  
3-NBA delivered i.p. is absorbed via the mesenteric veins and lymphatic systems, and passes 
through the liver. Thus, its concentration and effect in this tissue should be higher than in the distal 
tissues such as lung and kidney. Indeed, the induction of NQO1 and CYP1A1 in rat liver after 
identical i.p. treatment was up to 5- and 2-fold higher than in lungs and kidneys, respectively 
(Stiborová et al., 2006, present paper). Since exposure to 3-NBA occurs primarily via the 
respiratory tract and inhaled particles, a study evaluating the potential of 3-NBA administered via 
intratracheal instillation on enzymes capable of reducing 3-NBA or oxidising 3-ABA is under way 
in our laboratory. 
In conclusion, the results of the present study show for the first time that 3-NBA is capable of 
inducing NQO1 and CYP1A1 in rat lung and kidney. These enzymes we found to be the 
predominant biotransformating enzymes involved in the metabolic activation of 3-NBA and 3-ABA 
not only in these organs in rats (present study), but also in the liver of both rats and humans (Arlt et 
al., 2004b; 2005; Stiborová et al., 2006). By 3-NBA exposure, the metabolic activation of 3-NBA 
itself and its reductive metabolite 3-ABA to reactive species forming DNA adducts is increased, 
thereby enhancing their genotoxic and carcinogenic potential.  
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Table 1   
Effect of the NQO1 inhibitor dicoumarol and the XO inhibitor allopurinol on DNA adduct 
formation by 3-NBA in rat pulmonary and renal cytosols 
 
 Total RALa (mean/108 nucleotides) 
Cofactor/inhibitor added Pulmonary cytosol Renal cytosol 
NADPH only   2.69 ± 0.19    4.82 ± 0.36  
NADPH + dicoumarol     0.29 ± 0.02*    0.33 ± 0.03* 
HX only  0.58 ± 0.05   1.78 ± 0.12  
HX + allopurinol   0.59 ± 0.05  1.79 ± 0.20  
 
aRAL, relative adduct labelling. The results are presented as the mean ± SE of triplicate in-vitro 
incubations. 
*Significantly different from control incubations without inhibitor: p<0.001 (Student’s t-test) 
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Table 2 
Specific CYP1A1 activities a in kidney and lung microsomes of control and 3-NBA-treated rats 
 
 
CYP                                      Control rat                                     3-NBA-treated rat 
activity         Kidney                         Lung                    Kidney                              Lung 
                                                       
 
EROD                    9.4 ± 0.4                    4.6 ± 0.5               50.2 ± 1.8                         29.9 ± 2.1 
                                                                                                 (5.3)*                                                (6.5)* 
   
  
Sudan I                   9.3 ± 1.0                   4.7 ± 0.5               30.3 ± 2.3                          29.8 ± 2.8 
oxidation                                                                                    (3.2)*                                                (6.3)* 
 
 
aEach value (pmol of reaction product per min per mg protein) represents the mean ± SE of 
triplicate measurements. Numbers in parentheses represents the fold increase over the control 
activity caused by the pre-treatment with 3-NBA (40 mg/kg bw). 
*Significantly different from controls: p<0.001 (Student’s t-test). 
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Table 3 
NQO1 specific activity in rat renal and pulmonary cytosol 
 
 
 
            Control rat                                    3-NBA-treated rat  
                                                      0.4 mg/kg                 4 mg/kg                     40 mg/kg 
 
 
Kidney          0.09 ± 0. 01      0.15 ± 0. 01    0.15 ± 0. 01                 0.23 ± 0. 02        
                                                         (1.7) *                     (1.7)*                          (2.5)** 
   
  
Lung           0.05 ± 0.01            0.06 ± 0.01               0.06 ± 0.01      0.09 ± 0.01  
                                                          (1.2)                                      (1.2)                            (1.8)* 
 
 
The results (units per mg) are averages and SEs of five parallel measurements. Enzyme 
activities with menadione as a substrate was assayed as described in Materials and Methods. One 
unit of NQO1 is defined to reduce 1 µmol of NADPH per min/mg protein in the presence of 
menadione as substrate at 37°C. 
*Significantly different from controls: p<0.05 (Student’s t-test). 
**Significantly different from controls: p<0.01 (Student’s t-test).
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Table 4 
Expression of mRNA of CYP1A1 and NQO1 
___________________________________________________________________________ 
                                                                 CYP1A1                                   NQO1                     
                                                       ∆cT
a
                                
Fold                  ∆cT                           Fold               
                                                                                   Change                                      Change                    
___________________________________________________________________________                                                  
Control rats                                   
Kidney                                       4.45 ± 0.36                   -                9.37 ± 0.67               -         
Lung                                        10.48 ± 0.16                   -                5.44 ± 0.34                -         
 
3-NBA-treated rats 
Kidney                                       2.60 ± 0.65                  3.6**           9.07 ± 0.22              1.2*                  
Lung                                          8.51 ± 0.70                  3.9**           4.98 ± 0.21              1.4** 
___________________________________________________________________________ 
 
aResults shown are mean ± SD from data found for three rats (control and treated with 40 mg of 3-
NBA/kg bw). 
*Significantly different from controls: p<0.05 (Student’s t-test). 
**Significantly different from controls: p<0.01 (Student’s t-test)
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Legends to Figures 
Fig. 1. Pathways of metabolic activation and DNA adduct formation of 3-nitrobenzanthrone 
and 3-aminobenzanthrone. See text for details. 3-NBA, 3-nitrobenzanthrone; 3-ABA, 
3-aminobenzanthrone; NQO1, NAD(P)H:quinone oxidoreductase; NAT, N,O-
acetyltransferases; SULT, sulfotransferase; COX-1, cyclooxygenase 1; CYP, 
cytochrome P450; LPO, lactoperoxidase; MPO, myeloperoxidase; POR, 
NADPH:cytochrome P450 oxidoreductase; R = -COCH3 or -SO3H; dA-N6-ABA, 2-
(2’-deoxyadenosin-N6-yl)-3-aminobenzanthrone; dG-N2-ABA, N-(2’-deoxyguanosin-
N2-yl)-3-aminobenzanthrone; dG-C8-N-ABA, N-(2’-deoxyguanosin-8-yl)-3-
aminobenzanthrone.   
Fig. 2. Autoradiographic profiles of DNA adducts generated (A) by 3-NBA after its 
activation with cytosols isolated from lungs of rats treated with 40 mg/kg bw of 3-
NBA and NADPH, and (B) by 3-ABA after its activation with microsomes isolated 
from lungs of rats treated with 40 mg/kg bw of 3-NBA and NADPH by using the 
butanol enrichment version of the 32P-postlabelling assay. Spot 1 = dA-N6-ABA, 
spot 3 = dG-N2-ABA, spots 4/5 = dG-C8-N-ABA. (For structures of adducts see 
legend to Fig. 1) 
Fig. 3. The effect of cofactors of NQO1 and XO on the 3-NBA-DNA adduct formation in 
pulmonary (A) and renal cytosols (B) of control (uninduced) rats. (F = fold increase 
in DNA binding in comparison to DNA binding without cofactors). Mean ± SE 
shown in the figure represent total levels of DNA adducts (RAL, relative adduct 
labelling) of three determinations. *p<0.05, **p<0.01, ***p<0.001 (Student’s t-
test). HX, hypoxanthine. 
Fig. 4. DNA adduct formation by 3-NBA activated with cytosols isolated from lungs (A) 
and kidneys (B) of rats, control (uninduced) or pretreated with 40 mg/kg bw of 3-
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NBA and the DNA-adduct levels obtained by adding either PAPS as a cofactor for 
SULTs or acetyl-CoA as a cofactor for NATs. Mean ± SE shown in the figure 
represent total levels of DNA adducts (RAL, relative adduct labelling) of three 
determinations. *p<0.05, **p<0.01 (Student’s t-test). 
Fig. 5. DNA adduct formation by 3-ABA activated with microsomes isolated from lungs 
(A) and kidneys (B) of rats, control (uninduced) or pretreated with 40 mg/kg bw of 
3-NBA  F = fold higher DNA adducts levels in microsomes from 3-NBA-treated rats 
compared to control (uninduced) rats. Mean ± SE shown in the figure represent total 
levels of DNA adducts (RAL, relative adduct labelling) of three determinations. 
None = without cofactor; AA = arachidonic acid; α-NF = α-naphthoflavone; IM = 
indomethacin. ND = not detected. *p<0.05, **p<0.01, ***p<0.001 (Student’s t-
test). 
Fig. 6. DNA adduct formation by 3-ABA activated with cytosols isolated from lungs (A) 
and kidneys (B) of rats, control (uninduced) or pretreated with 40 mg/kg bw of 3-
NBA. Mean ± SE shown in the figure represent total levels of DNA adducts (RAL, 
relative adduct labelling) of three determinations. 
Fig. 7. Induction of CYP1A1 (A,B) and NQO1 (C,D) in lungs (A,C) and kidney (B,D) of 
rats treated with 0.4, 4 or 40 mg/kg bw of 3-NBA determined by Western blots as 
described in the Material and methods section. Values represent mean ± SD obtained 
from lungs and kidneys of three rats (n=3). Inset: immunoblots of microsomal 
CYP1A1 and cytosolic NQO1 from untreated and 3-NBA-treated rats stained with 
antibody against rat CYP1A1 and human NQO1. Values significantly different from 
control: *p<0.05, **p<0.01, ***p<0.001 (Student’s t-test). 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7  
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Supporting Table S1.  
a) Effect of enzyme cofactors on DNA adduct formation by 3-NBA in rat lung cytosol 
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced lung cytosol  without 
cofactor 
0.084 ± 
0.011 
0.054 ± 
0.009 
0.151 ± 
0.012 
0.075 ± 
0.010 
0.074 ± 
0.010 
0.443 ± 
0.034 
uninduced lung cytosol + 
NADPH  
0.189 ± 
0.015 
0.298 ± 
0.021 
1.210 ± 
0.102 
0.882 ± 
0.068 
0.110 ± 
0.011 
2.688 ± 
0.190 
uninduced lung cytosol + 
NADH 
0.199 ± 
0.018 
0.317 ± 
0.029 
0.799 ± 
0.078 
0.844 ± 
0.078 
0.170 ± 
0.018 
2.309 ± 
0.211 
uninduced lung cytosol  
+ HX 
0.082  ± 
0.011 
0.109 ± 
0.010 
0.264 ± 
0.023 
0.083 ± 
0.008 
0.042 ± 
0.005 
0.580 ± 
0.050 
uninduced lung cytosol + 
NADPH + PAPS 
0.511 ± 
0.048 
0.977 ± 
0.101 
1.989 ± 
0.132 
1.989 ± 
0.165 
0.386 ± 
0.030 
5.852 ± 
0.476 
uninduced lung cytosol + 
NADPH + acetylCoA 
5.13 ± 
0.498 
7.71 ± 
0.671 
13.88 ± 
1.151 
17.826 
± 1.482 
3.712 ± 
0.301 
48.656 
± 4.426 
3-NBA lung cytosol + NADPH 0.743 ± 
0.070 
0.377 ± 
0.048 
1.732 ± 
0.152 
1.0596 
± 0.098 
0.7992 ± 
0.081 
4.7108 
± 0.421 
3-NBA lung cytosol + NADPH 
+ PAPS 
1.10 ± 
0.107 
0.99 ± 
0.089 
2.616 ± 
0.216 
2.921 ± 
0.252 
0.912 ± 
0.099 
8.545 ± 
0.698 
3-NBA lung cytosol + NADPH 
+ acetylCoA 
11.836 
± 1.021 
9.885 ± 
0.954 
25.819 
± 2.101 
28.92 ± 
2.231 
1.223 ± 
0.108 
88.75 ± 
7.132 
 
b) Effect of enzyme cofactors on DNA adduct formation by 3-NBA in rat kidney cytosol 
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced kidney cytosol  
without cofactor 
0.148 ± 
0.013 
0.310 ± 
0.289 
0.823 ± 
0.754 
0.449 ± 
0.398 
0.066 ± 
0.010 
1.796 ± 
0.154 
uninduced kidney cytosol + 
NADPH  
0.467 ± 
0.051 
0.698 ± 
0.061 
1.797 ± 
0.142 
1.483 ± 
0.132 
0.392 ± 
0.034 
4.82 ± 
0.360 
uninduced kidney cytosol + 
NADH 
0.464 ± 
0.049 
0.690 ± 
0.063 
1.788 ± 
0.148 
1.459 ± 
0.140 
0.400 ± 
0.041 
4.80 ± 
0.387 
uninduced kidney cytosol + HX 0.145 ± 
0.014 
0.305 ± 
0.029 
0.813 ± 
0.009 
0.452 ± 
0.033 
0.066 ± 
0.053 
1.781 ± 
0.122 
uninduced kidney cytosol + 
NADPH + PAPS 
0.749 ± 
0.064 
1.369 ± 
0.327 
2.978 ± 
0.234 
3.061 ± 
0.300 
0.583 ± 
0.052 
8.74 ± 
0.782 
uninduced kidney cytosol + 
NADPH + acetylCoA 
12.80 ± 
1.001 
38.63 ± 
3.123 
43.65 ± 
4.176 
46.61 ± 
4.101 
1.38 ± 
0.151 
143.08 ± 
11.201 
3-NBA kidney cytosol + 
NADPH 
0.945 ± 
0.798 
1.40 ± 
0.129 
3.55 ± 
0.310 
3.33 ± 
0.323 
0.72 ± 
0.062 
9.945 ± 
0.899 
3-NBA kidney cytosol + 
NADPH + PAPS 
2.08 ± 
0.201 
2.94 ± 
0.232 
8.160 ± 
0.754 
7.03 ± 
0.678 
1.80 ± 
0.201 
20.21 ± 
1.912 
3-NBA kidney cytosol + 
NADPH + acetylCoA 
27.405 
± 2.43 
42.00 ± 
4.100 
104.725 
± 9.43 
99.234 
± 9.110 
20.88 ± 
2.06 
294.244 ± 
28.032 
 
a Mean RAL (relative adduct labelling) and standard deviation of triplicate in-vitro 
incubations; spot 1 = dA-N6-ABA, spot 3 = dG-N2-ABA, spots 4/5 = dG-C8-N-ABA. 
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Supporting Table S2.  
a) DNA adduct formation by 3-ABA activated by lung microsomes of rats either 
uninduced or induced by 3-NBA  
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced lung microsomes 
without cofactor 
 
uninduced lung microsomes + 
NADPH 
 
uninduced lung microsomes + 
NADPH + α-NF 
 
uninduced lung microsomes + 
arachidonic acid 
 
uninduced lung microsomes + 
arachidonic acid + indomethacin 
 
NDb 
 
 
0.072 ± 
0.008 
 
0.030 ± 
0.003 
 
0.035 ± 
0.004 
 
0.030 ± 
0.003 
 
ND 
 
 
0.062 ± 
0.006 
 
0.030 ± 
0.003 
 
0.035 ± 
0.004 
 
0.030 ± 
0.003 
 
ND 
 
 
0.154 ± 
0.012 
 
0.110 ± 
0.010 
 
0.101 ± 
0.010 
 
0.100 ± 
0.014 
 
ND 
 
 
0.059 ± 
0.004 
 
0.080 ± 
0.006 
 
0.026 ± 
0.003 
 
0.020 ± 
0.002 
 
ND 
 
 
0.055 ± 
0.005 
 
0.010 ± 
0.001 
 
0.026 ± 
0.003 
 
ND 
 
ND 
 
 
0.402 ± 
0.037 
 
0.260 ± 
0.021 
 
0.223 ± 
0.025 
 
0.180 ± 
0.021 
 
3-NBA lung microsomes 
without cofactor 
 
3-NBA lung microsomes + 
NADPH  
 
3-NBA lung 
microsomes + NADPH + α-NF 
 
3-NBA lung microsomes + 
arachidonic acid 
 
3-NBA lung microsomes + 
arachidonic acid + indomethacin 
ND 
 
 
0.123 ± 
0.013 
 
0.052 ± 
0.006 
 
0.051 ± 
0.005 
 
0.050 ± 
0.005 
ND 
 
 
0.333 ± 
0.029 
 
0.083 ± 
0.009 
 
0.059 ± 
0.006 
 
0.050 ± 
0.005 
 
 
ND 
 
 
0.786 ± 
0.071 
 
0.291 ± 
0.025 
 
0.101 ± 
0.012 
 
0.100 ± 
0.012 
 
 
 
 
ND 
 
 
0.883± 
0.092 
 
0.121 ± 
0.013 
 
0.105 ± 
0.011 
 
0.095 ± 
0.010 
 
 
 
 
 
ND 
 
 
0.193 ± 
0.015 
 
0.065 ± 
0.008 
 
0.026 ± 
0.003 
 
0.023 ± 
0.003 
 
 
 
 
ND 
 
 
2.018 ± 
0.194 
 
0.612 ± 
0.065 
 
0.342 ± 
0.036 
 
0.218 ± 
0.029 
       
 
a Mean RAL (relative adduct labelling) of triplicate in-vitro incubations; spot 1 = dA-N6-
ABA, spot 3 = dG-N2-ABA, spots 4/5 = dG-C8-N-ABA. 
b ND = not detected. 
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Supporting Table S2.  
b) DNA adduct formation by 3-ABA activated by kidney microsomes of rats either 
uninduced or induced by 3-NBA  
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced without cofactor 
 
 
uninduced s + NADPH 
 
 
uninduced + NADPH + α-NF 
 
 
uninduced + arachidonic acid 
 
 
uninduced + arachidonic acid + 
indomethacin 
 
NDb 
 
 
0.067 ± 
0.007 
 
0.032 ± 
0.003 
 
0.055 ± 
0.006 
 
0.050 ± 
0.006 
 
ND 
 
 
0.087 ± 
0.009 
 
0.050 ± 
0.006 
 
0.096 ± 
0.010 
 
0.086 ± 
0.010 
 
ND 
 
 
0.377 ± 
0.032 
 
0.123 ± 
0.011 
 
0.197 ± 
0.018 
 
0.172 ± 
0.018 
 
ND 
 
 
0.154 ± 
0.014 
 
0.065 ± 
0.006 
 
0.088 ± 
0.003 
 
0.080 ± 
0.002 
 
ND 
 
 
0.025 ± 
0.003 
 
0.012 ± 
0.001 
 
ND 
 
 
ND 
 
ND 
 
 
0.710 ± 
0.078 
 
0.282 ± 
0.029 
 
0.436 ± 
0.045 
 
0.388 ± 
0.041 
 
3-NBA microsomes without 
cofactor 
 
3-NBA microsomes + NADPH  
 
 
3-NBA microsomes + NADPH 
+ α-NF 
 
3-NBA microsomes + 
arachidonic acid 
 
3-NBA microsomes + 
arachidonic acid + indomethacin 
ND 
 
 
0.179 ± 
0.018 
 
0.062 ± 
0.006 
 
0.107 ± 
0.011 
 
0.100 ± 
0.010 
ND 
 
 
0.303 ± 
0.031 
 
0.101 ± 
0.010 
 
0.113 ± 
0.012 
 
0.080 ± 
0.009 
 
 
ND 
 
 
0.991 ± 
0.010 
 
0.203 ± 
0.024 
 
0.274 ± 
0.025 
 
0.265 ± 
0.028 
 
 
 
 
ND 
 
 
0.808± 
0.091 
 
0.180 ± 
0.017 
 
0.155 ± 
0.018 
 
0.130 ± 
0.012 
 
 
 
 
 
ND 
 
 
0.154 ± 
0.015 
 
0.035 ± 
0.004 
 
ND 
 
 
ND 
 
 
 
 
ND 
 
 
2.435 ± 
0.210 
 
0.581 ± 
0.060 
 
0.649 ± 
0.065 
 
0.575 ± 
0.058 
       
 
a Mean RAL (relative adduct labelling) of triplicate in-vitro incubations; spot 1 = dA-N6-
ABA, spot 3 = dG-N2-ABA, spots 4/5 = dG-C8-N-ABA. 
b ND = not detected. 
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Supporting Table S3.  
a) DNA adduct formation by 3-ABA activated by lung cytosols of rats either uninduced 
or induced by 3-NBA  
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced  
cytosol  
NDb ND ND ND ND ND 
uninduced  
cytosol + H2O2 
0.057± 
0.007 
0.072 ± 
0.008 
 
0.128 ± 
0.015 
 
0.066 ± 
0.008 
 
0.060 ± 
0.007 
 
0.383 ± 
0.045 
3-NBA  
cytosol + H2O2 
0.099 ± 
0.010 
0.086 ± 
0.010 
0.114 ± 
0.011 
0.114 ± 
0.012 
0.093 ± 
0.010 
0.506 ± 
0.051 
 
 
b) DNA adduct formation by 3-ABA activated by kidney cytosols of rats either 
uninduced or induced by 3-NBA  
 RALa (mean/108 nucleotides) 
 Spot 1 Spot 2 Spot 3 Spot 4 Spot 5 Total 
uninduced  
cytosol  
NDb ND ND ND ND ND 
uninduced  
cytosol + H2O2 
0.237± 
0.023 
0.233 ± 
0.023 
 
0.272 ± 
0.029 
 
0.163 ± 
0.014 
 
ND  0.905 ± 
0.110 
3-NBA  
cytosol + H2O2 
0.393 ± 
0.051 
0.210 ± 
0.021 
0.400 ± 
0.043 
0.200 ± 
0.022 
ND 1.203 ± 
0.134 
 
 
a Mean RAL (relative adduct labelling) of triplicate in-vitro incubations; spot 1 = dA-N6-
ABA, spot 3 = dG-N2-ABA, spots 4/5 = dG-C8-N-ABA. 
b ND = not detected. 
 
 
 
 
 
 
 
 
 
 
